BamSEC and AlphaSense Join Forces
Learn More

Relay Therapeutics Inc.

NASDAQ: RLAY    
Share price (12/23/24): $4.34    
Market cap (12/23/24): $726 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 38 pages Relay Therapeutics, Inc. Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Amendment No. Ar5 to Amended and Restated Collaboration and License Agreement
12/34/56
EX-10.3
from 10-Q 4 pages Relay Therapeutics, Inc. Retention Award Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Relay Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 10-Q 6 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Amendment No. Ar4 to Amended and Restated Collaboration and License Agreement [***]
12/34/56
EX-10.2
from 10-Q 5 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark [***]
12/34/56
EX-10.1
from 10-Q 6 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Amendment No. Ar3 to Amended and Restated Collaboration and License Agreement
12/34/56
EX-10.2
from 10-K 63 pages Relay Therapeutics, Inc. 2020 Stock Option and Incentive Plan
12/34/56
EX-10.5
from 10-Q 128 pages Lease by and Between Bmr-Hampshire, LLC, a Delaware Limited Liability Company and Relay Therapeutics, Inc., a Delaware Corporation
12/34/56
EX-10.2
from 10-Q 4 pages Relay Therapeutics, Inc. Retention Award Agreement
12/34/56
EX-10.4
from 10-Q 3 pages Amendment No. Ar2 to Amended and Restated Collaboration and License Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Relay Therapeutics, Inc. Retention Award Agreement
12/34/56
EX-10.14
from S-1 14 pages Registration Rights Agreement
12/34/56
EX-10.10
from S-1 5 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Amendment No. Ar1 to Amended and Restated Collaboration and License Agreement
12/34/56
EX-10.5
from S-1 2 pages Relay Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.10
from 10-K 121 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark [***]. Collaboration and License Agreement Between Genentech, Inc. and F. Hoffmann-La Roche Ltd and Relay Therapeutics, Inc. Dated as of December 11, 2020
12/34/56
EX-10.7
from 10-Q 11 pages Second Amendment to Lease
12/34/56
EX-10.8
from S-1/A 15 pages Employment Agreement
12/34/56
EX-10.5
from S-1/A 3 pages Relay Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.3
from S-1/A 14 pages Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan
12/34/56